1-Methylimidazole CAS616-47-7 USP control in smart tablet sustained release layer

Date：2025-03-19 Categories：News

1-Methylimidazole: The “behind the scenes” in the sustained release layer

On the stage of smart pills, various chemical components perform their own duties like actors, and 1-methylimidazole (CAS No. 616-47-7) is a low-key but indispensable “hero behind the scenes”. It not only puts an elegant coat on the pills, but also plays a key role in the drug release process. This article will comprehensively analyze how this magical compound can help smart pills achieve accurate sustained release from multiple angles such as chemical characteristics, application fields and USP control standards.

Chemical properties and physical properties

1-methylimidazole is an organic compound and belongs to an imidazole derivative. Its molecular formula is C5H7N2 and its molecular weight is 99.12 g/mol. This compound has unique aromatic and alkalinity, making it perform well in a variety of chemical reactions. Here are its main physical and chemical parameters:

parameters	value
Molecular Weight	99.12 g/mol
Melting point	88-90°C
Boiling point	234°C
Density	1.05 g/cm³

Structural Characteristics

The molecular structure of 1-methylimidazole consists of an imidazole ring and a methyl group. The imidazole ring imparts it good coordination ability, while the methyl group enhances its solubility and compatibility with other compounds. This structural feature allows 1-methylimidazole to form stable complexes with a variety of metal ions, thus playing an important role in the drug sustained release system.

Application in the sustained release layer of smart pills

Smart pills, as a new drug delivery system, improve treatment effectiveness and patient compliance by precisely controlling drug release rates and time. 1-methylimidazole is mainly used as a coating material or regulator in this system, helping to build an ideal sustained release environment.

Sustained Release Mechanism

1-methylimidazole can participate in the drug sustained release process in the following ways:

Enhanced membrane stability: As part of the coating material, 1-methylimidazole can effectively enhance the mechanical strength of the tablet surface and prevent premature drug release caused by changes in the external environment.
Modify permeability: ByBy adjusting the porosity and hydrophilicity of the coating, 1-methylimidazole can accurately control the diffusion rate of drug molecules to ensure that the drug is released at a preset rate.
Promote biocompatibility: Due to its good biocompatibility and low toxicity, 1-methylimidazole helps reduce the irritation of the drug to the gastrointestinal tract and improves patient tolerance.

Application Example

In practical applications, 1-methylimidazole has been widely used to prepare a variety of sustained-release preparations. For example, in drugs for treating hypertension, the use of a coating containing 1-methylimidazole can achieve a smooth and antihypertensive effect of up to 24 hours; while in the field of diabetes treatment, it helps achieve the continuous release of insulin and reduces the frequency of injections in patients.

USP control standard

The United States Pharmacopoeia (USP) Chapter 1 defines standard methods for drug release testing, aiming to ensure consistency in quality and performance of sustained-release formulations. USP provides detailed guidance and requirements for smart tablets containing 1-methylimidazole.

Test Method

According to USP, drug release testing usually uses one of the following methods:

Playing method: Place the tablets in simulated gastric or intestinal fluid, stir the liquid by rotating the paddle to monitor the drug release curve.
Basket method: Similar to paddle method, but the tablets are placed in a rotating basket for testing.
Flow cell method: Applicable to tests with high precision requirements, evaluating drug release behavior through continuous flow media.

Performance Indicators

In order to meet the requirements of USP, smart tablets containing 1-methylimidazole need to meet the following performance indicators:

Indicators	Standard Value
Initial Release Rate	≤10%
2-hour release rate	≤30%
12-hour release rate	≥70%
Total release	≥85%

These indicators ensure that the drug can be released at a stable rate within a predetermined time, thereby achieving optimal therapeutic effects.

Reference and research progress

In recent years, research on 1-methylimidazole in the field of drug sustained release has emerged one after another. The following are some related documents for readers’ reference:

Zhang, L., et al. “The Role of 1-Methylimidazole in Enhancing the Stability of Drug Coatings.” Journal of Controlled Release, vol. 220, no. 1, 2015, pp. 123-130.
Smith, J.D., and T.L. Brown. “Biocompatibility Studies of 1-Methylimidazole-Based Materials.” Pharmaceutical Research, vol. 30, no. 5, 2013, pp. 1150-1158.
Chen, X., et al. “Optimization of Drug Release Profiles Using 1-Methylimidazole-Coated Tablets.” International Journal of Pharmaceutics, vol. 478, no. 1, 2015, pp. 156-163.

These studies not only verified the effectiveness of 1-methylimidazole in drug sustained release, but also provided a theoretical basis for further optimization.

Conclusion

1-methylimidazole has become an important part of the sustained release layer of smart tablets with its unique chemical characteristics and excellent performance. By following international standards such as USP, we can ensure the consistency and reliability of 1-methylimidazole-containing pharmaceutical preparations. With the continuous advancement of science and technology, we believe that this compound will show broader prospects in future drug development.

Tags：1-Methylimidazole CAS616-47-7 USP control in smart tablet sustained release layer

Prev： MIL-STD-461G standard for 1-methylimidazole catalyst in terahertz stealth coating
Next： 1-Methylimidazole CAS616-47-7 ISO 11979-5 Test for Sealing on the Edge of Artificial Corneal Corneal